| Trial ID: | L0320 |
| Source ID: | NCT04761848
|
| Associated Drug: |
Cilostazol
|
| Title: |
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty Liver, Nonalcoholic
|
| Interventions: |
Drug: Cilostazol 50 MG|Drug: Placebo
|
| Outcome Measures: |
Hepatic transaminases|Serum ferritin|Lipid profile|Glycated haemoglobin|Serum stem cell transforming factor beta|Adverse effects|FAM19A5 serum level
|
| Sponsor/Collaborators: |
Sadat City University
|
| Gender: |
All
|
| Age: |
18 Years to 60 Years ?? (Adult)
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
120
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
February 16, 2021
|
| Completion Date: |
December 31, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 22, 2022
|
| Locations: |
Faculty of Pharmacy, Shib??n Al Kawm, Menoufia, Egypt
|
| URL: |
https://ClinicalTrials.gov/show/NCT04761848
|
